{"preliminary_commentary":{"by_channel":{"youtube":4,"x_thread":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05170204\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["alectinib"],["entrectinib"]],"indication":"unresectable stage III non-small cell lung cancer","name":"HORIZON 1","nct_id":"NCT05170204","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=horizon-1-nct05170204. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HORIZON 1","arms":[{"description":"Participants will receive alectinib 600 milligrams (mg) orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first","label":"Cohort A1: Anaplastic Lymphoma Kinase (ALK)-positive (Alectinib Arm)","type":"EXPERIMENTAL"},{"description":"Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks (Q4W) until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first","label":"Cohort A1: ALK-positive (Durvalumab Arm)","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.\n\nCohort A2 has been closed to enrollment.","label":"Cohort A2: ROS Proto-oncogene 1 (ROS 1)-positive (Entrectinib Arm)","type":"EXPERIMENTAL"},{"description":"Participants will receive 1500 mg of IV durvalumab Q4W until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first\n\nCohort A2 has been closed to enrollment.","label":"Cohort A2: ROS 1-positive (Durvalumab Arm)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-06-16","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":68,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Alectinib","otherNames":["RO5424802; Alecensa®"],"type":"DRUG"},{"name":"Entrectinib","otherNames":["RO7102122; Rozlytrek®"],"type":"DRUG"},{"name":"Durvalumab","otherNames":["IMFINZI®"],"type":"DRUG"}],"last_update":"2026-08-05","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-06-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS), as Determined by Blinded Independent Central Review (BICR) per Response Evaluation Criterial in Solid Tumors Version 1.1 (RECIST V1.1)","timeFrame":"From randomization to the first documented disease progression or death from any cause, whichever occurs first (up to 3 years)"}],"references":[],"start_date":{"date":"2022-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT05170204"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/horizon-1-nct05170204"}